Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Glioblastoma × Nivolumab × Clear all

Phase

Phase 1 15 Phase 2 11 Phase 1/2 5 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 25 Melanoma 24 Carcinoma, Renal Cell 15 Stomach Neoplasms 9 Lung Neoplasms 9 Squamous Cell Carcinoma of Head and Neck 6 Kidney Neoplasms 5 Carcinoma, Hepatocellular 5 Brain Neoplasms 5 Urinary Bladder Neoplasms 4 Mesothelioma 4 Adenocarcinoma Of Esophagus 4 Skin Neoplasms 3 Neoplasms 3 Neoplasm Metastasis 3 Head and Neck Neoplasms 3 Anus Neoplasms 3 Various Advanced Cancer 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Mesothelioma, Malignant 2 Liver Neoplasms 2 Hodgkin Disease 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Colonic Neoplasms 2 Carcinoma 2 Anal Canal Carcinoma 2 Adenocarcinoma 2 von Hippel-Lindau Disease 1 Uveal Melanoma 1

Interventions

Temozolomide 39 Radiotherapy 18 Lomustine 12 Bevacizumab 11 Carmustine 8 Radiation 7 Procarbazine 4 Magnetic Resonance Spectroscopy 4 Surgical Procedures, Operative 3 pembrolizumab 2 depatuxizumab mafodotin 2 Tf-CRM107 2 Specimen Handling 2 Radiotherapy, Intensity-Modulated 2 Drug Therapy 2 Dihematoporphyrin Ether 2 DNA Methylation 2 Carboplatin 2 ABT-414 2 trans-sodium crocetinate 1 tofacitinib 1 sargramostim 1 rindopepimut 1 niraparib 1 marizomib 1 enzastaurin 1 edotecarin 1 contrast agent BR1 1 cediranib 1 carmustine, poliferprosan 20 drug combination 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02017717 2025-04-04

CheckMate 143

Bristol-Myers Squibb

Phase 3 Completed

529 enrolled 28 charts

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡